Aberrant expression of SOX9 is associated with gastrokine 1 inactivation in gastric cancers

Gastric Cancer

Volumn 17, Issue 2, 2014, Pages 247-254

  Choi, Yoo Jin ^a   Song, Jae Hwi ^a   Yoon, Jung Hwan ^a   Choi, Won Suk ^a   Nam, Suk Woo ^a   Lee, Jung Young ^a   Park, Won Sang ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Expression; Gastric cancer; GKN1; SOX9

Indexed keywords

GKN1 PROTEIN, HUMAN; PEPTIDE HORMONE; SOX9 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX9; TUMOR MARKER;

CANCER STAGING; ENZYME IMMUNOASSAY; HUMAN; LYMPH NODE METASTASIS; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; STOMACH TUMOR; SURVIVAL RATE; TUMOR CELL CULTURE; TUMOR INVASION;

HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PEPTIDE HORMONES; PROGNOSIS; SOX9 TRANSCRIPTION FACTOR; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84898770149     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-013-0277-3     Document Type: Article

References (24)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30. (Pubitemid 40310185)
2. Jung KW, Park SH, Won YJ, Kong HJ, Lee JY, Seo HG, et al. Prediction of cancer incidence and mortality in Korea, 2012. Cancer Res Treat. 2012;1:25-31.
3. Yuasa Y. Control of gut differentiation and intestinal-type gastric carcinogenesis. Nat Rev Cancer. 2003;3:592-600. (Pubitemid 37328831)
4. Katoh M. Wnt/PCP signaling pathway and human cancer. Oncol Rep. 2005;14:1583-8.
5. Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev. 2007;17:45-51. (Pubitemid 46109296)
6. Yoon JH, Song JH, Zhang C, Jin M, Kang YH, Nam SW, et al. Inactivation of the gastrokine 1 gene in gastric adenomas and carcinomas. J Pathol. 2011;223:618-25.
7. Yoon JH, Kang YH, Choi YJ, Park IS, Nam SW, Lee JY, et al. Gastrokine 1 functions as a tumor suppressor by inhibition of epithelial-mesenchymal transition in gastric cancers. J Cancer Res Clin Oncol. 2011;137:1697-704.
8. Hersmus R, Kalfa N, de Leeuw B, Stoop H, Oosterhuis JW, de Krijger R, et al. FOXL2 and SOX9 as parameters of female and male gonadal differentiation in patients with various forms of disorders of sex development (DSD). J Pathol. 2008;215:31-8. (Pubitemid 351619873)
9. Jay P, Berta P, Blache P. Expression of the carcinoembryonic antigen gene is inhibited by SOX9 in human colon carcinoma cells. Cancer Res. 2005;65:2193-8. (Pubitemid 40490127)
10. Kormish JD, Sinner D, Zorn AM. Interactions between SOX factors and Wnt/beta-catenin signaling in development and disease. Dev Dyn. 2010;239:56-68.
11. Moniot B, Biau S, Faure S, Nielsen CM, Berta P, Roberts DJ, et al. SOX9 specifies the pyloric sphincter epithelium through mesenchymal-epithelial signals. Development (Camb). 2004;131:3795-804. (Pubitemid 39199386)
12. Sashikawa Kimura M, Mutoh H, Sugano K. SOX9 is expressed in normal stomach, intestinal metaplasia, and gastric carcinoma in humans. J Gastroenterol. 2011;46:1292-9.
13. Sun M, Uozaki H, Hino R, Kunita A, Shinozaki A, Ushiku T, et al. SOX9 expression and its methylation status in gastric cancer. Virchows Arch. 2012;460:271-9.
14. Franco AT, Israel DA, WashingtonMK, Krishna U, Fox JG, Rogers AB, et al. Activation of beta-catenin by carcinogenic Helicobacter pylori. Proc Natl Acad Sci USA. 2005;102:10646-51. (Pubitemid 41061608)
15. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature (Lond). 1999;398:422-6. (Pubitemid 29180374)
16. Blache P, van de Wetering M, Duluc I, Domon C, Berta P, Freund JN, et al. SOX9 is an intestine crypt transcription factor, is regulated by the Wnt pathway, and represses the CDX2 and MUC2 genes. J Cell Biol. 2004;166:37-47. (Pubitemid 38931915)
17. Wang L, He S, Yuan J, Mao X, Cao Y, Zong J, et al. Oncogenic role of SOX9 expression in human malignant glioma. Med Oncol. 2012;29:3484-90.
18. Sun L, Mathews LA, Cabarcas SM, Zhang X, Yang A, Zhang Y, et al. Epigenetic regulation of SOX9 by the NF-κB signaling pathway in pancreatic cancer stem cells. 2013 (in press).
19. Yu CC, Tsai LL, Wang ML, Yu CH, Lo WL, Chang YC, et al. miR145 targets the SOX9/ADAM17 axis to inhibit tumor initiating cells and IL-6-mediated paracrine effects in head and neck cancer. Cancer Res. 2013;73:3425-40.
20. Lu B, Fang Y, Xu J, Wang L, Xu F, Xu E, et al. Analysis of SOX9 expression in colorectal cancer. Am J Clin Pathol. 2008;130:897-904.
21. Wang H, Leav I, Ibaragi S, Wegner M, Hu GF, Lu ML, et al. SOX9 is expressed in human fetal prostate epithelium and enhances prostate cancer invasion. Cancer Res. 2008;68:1625-30. (Pubitemid 351416545)
22. Chakravarty G, Moroz K, Makridakis NM, Lloyd SA, Galvez SE, Canavello PR, et al. Prognostic significance of cytoplasmic SOX9 in invasive ductal carcinoma and metastatic breast cancer. Exp Biol Med. 2011;236:145-55.
23. Radulescu S, Ridgway RA, Cordero J, Athineos D, Salgueiro P, Poulsom R, et al. Acute Wnt signalling activation perturbs differentiation within the adult stomach and rapidly leads to tumour formation. Oncogene. 2013;32:2048-57.
24. Panza A, Pazienza V, Ripoli M, Benegiamo G, Gentile A, Rosaria M, et al. Interplay between SOX9, β-catenin, and PPARγ activation in colorectal cancer. Biochim Biophys Acta. 2013;1833:1853-65.